Evidence map›Paper›PMID 31661773›Full record

ArticleInternational journal of molecular sciences2019

The Influence of a Nanopatterned Scaffold that Mimics Abnormal Renal Mesangial Matrix on Mesangial Cell Behavior.

Chia-Jung Chang, Rin Minei, Takeshi Sato, Akiyoshi Taniguchi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chia-Jung ChangDepartment of Nanoscience and Nanoengineering, Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan. CHANG.Chiajung@nims.go.jp.ORCID 0000-0002-2276-3506
Rin MineiGlycobiology Laboratory, Nagaoka University of Technology, 1603-1 Kamitomiokamachi, Nagaoka, Niigata 940-2137, Japan. s163385@stn.nagaokaut.ac.jp.
Takeshi SatoGlycobiology Laboratory, Nagaoka University of Technology, 1603-1 Kamitomiokamachi, Nagaoka, Niigata 940-2137, Japan. taksato@vos.nagaokaut.ac.jp.
Akiyoshi TaniguchiDepartment of Nanoscience and Nanoengineering, Graduate School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan. taniguchi.akiyoshi@nims.go.jp.ORCID 0000-0001-7835-2522
Nagaoka University of Technology · JPWaseda University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The alteration of mesangial matrix (MM) components in mesangium, such as type IV collagen (COL4) and type I collagen (COL1), is commonly found in progressive glomerular disease. Mesangial cells (MCs) responding to altered MM, show critical changes in cell function. This suggests that the diseased MM structure could play an important role in MC behavior. To investigate how MC behavior is influenced by the diseased MM 3D nanostructure, we fabricated the titanium dioxide (TiO

Indexed as

ActinsAnimalsCell ProliferationCells, CulturedCollagen Type ICollagen Type IVFibronectinsGlomerular MesangiumIntegrinsKidney DiseasesLamininMesangial CellsMiceNanostructuresTitaniumTransforming Growth Factor betaActinsalpha-smooth muscle actin, mouseCollagen Type ICollagen Type IVFibronectinsIntegrinsLamininlaminin ATitaniumtitanium dioxideTransforming Growth Factor betamesangial matrixTiO2-based nanopatterntype I collagen (COL1)type IV collagen (COL4)

Identifiers

PMID31661773
PMCPMC6861955
OpenAlexW2981816862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.